Printer Friendly

AstraZeneca reports on detailed results of phase III DAPA HF trial.

M2 EQUITYBITES-September 3, 2019-AstraZeneca reports on detailed results of phase III DAPA HF trial


AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, reported on Monday that detailed results from the landmark phase III DAPA-HF trial showed Farxiga (dapagliflozin), on top of standard of care, reduced both the incidence of cardiovascular death and the worsening of heart failure.

The company said DAPA-HF is the first outcomes trial with an SGLT2 inhibitor investigating the treatment of heart failure in patients with reduced ejection fraction (HFrEF), with and without type-2 diabetes (T2D). Farxiga is currently approved to treat patients with T2D.

According to the company, topline results announced in August 2019 showed DAPA-HF met the primary endpoint. The detailed results of the trial presented at the ESC Congress 2019 in Paris, France, showed Farxiga reduced the composite of cardiovascular (CV) death or worsening of heart failure by 26% (p

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 3, 2019
Previous Article:BMW reveals details of the i3s Edition RoadStyle for 2020 model year.
Next Article:Hyundai reports August 2019 global sales.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |